Authors: Wataru Kikushima Yoichi Sakurada Atsushi Sugiyama Naohiko Tanabe Seigo Yoneyama Hiroyuki Iijima
Publish Date: 2016/09/23
Volume: 61, Issue: 1, Pages: 61-66
Abstract
To investigate the incidence risk factors and effect on visual improvement of retreatment within 60 months after initial photodynamic therapy PDT combined with intravitreal ranibizumab IVR in eyes with treatmentnaïve polypoidal choroidal vasculopathy PCVWe retrospectively reviewed the medical records of 61 eyes from 60 patients with PCV who were followed up for at least 12 months after undergoing combination therapy Retreatment including combination therapy or IVR alone was administered if residual or recurrent exudative changes were presentDuring the followup period mean 44 ± 13 months median 48 months 46 eyes 754 underwent retreatment Survival analysis revealed that the proportions of eyes that were retreatmentfree were 59 at the 12month visit 41 at the 24 month 31 at the 36 month and 20 at the 60month visit The median retreatmentfree period was 150 95 confidence interval CI 74–227 months and the mean period was 249 95 CI 193–306 months Cox regression analysis revealed that older age P = 0010 hazard ratio 106 CI 102–111 and male gender P = 0043 hazard ratio 241 CI 103–562 were associated with retreatment Visual improvement was significantly better in eyes without retreatment compared with those with retreatment at the 12 24 and 48month visits
Keywords: